|Videos|December 16, 2021
New Delivery Option for Ketamine
Author(s)Jeffrey Becker, MD
How can new formulations of ketamine impact patient care?
Advertisement
Jeffrey Becker, MD, discusses new formulations of ketamine for subcutaneous delivery and how ketamine works.
Dr Becker is cofounder and Chief Scientific Officer at Bexson Biomedical, Inc.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Psychiatric Times
1
Southern California Psychiatry: Review of New Agents in Schizophrenia and Dementia
2
AI in 2025: A Look Back With Allen Frances, MD
3
Programs for ST-905 and ST-905 for Schizophrenia and Depression Launched by Syremis Therapeutics
4
Latest Alzheimer Disease Data: Reports from CTAD 2025
5